In early September 2021, the Delta variant is the dominant SARS-CoV-2 strain in most countries. Unless otherwise stated, all information refers to COVID-19 vaccines in the context of infection with and transmission of the Delta variant.
Gliederung am Anfang
Vaccines – Efficacy – Adverse events – Special populations – Special Topics
As of 1 September 2021, four COVID-19 vaccines have been approved or authorized for emergency use in the EU or the US:
- The BioNTech/Pfizer vaccine. Trade name: Comirnaty™ (tozinameran, formerly known as BNT162b2)
- The Moderna vaccine, also known as mRNA-1273
- The AstraZeneca/University of Oxford vaccine. Trade name: Vaxzevria™/Covishield™ (formerly known as ChAdOx1 nCoV-19, AZD1222)
- The Johnson & Johnson (Janssen) vaccine, also known as Ad26.COV2.S
Outside the EU and the US, other vaccines have been approved, for example:
- BBIBP-CorV, Sinopharm and the Beijing Institute of Biological Products – first approved in China on 30 December 2020
- Covaxin, Bharat Biotech – first approved in India on 3 January 2021
- Sputnik-V, Gamaleya Research Institute – first approved in Russia, 28 December 2020
- Convidecia, CanSinoBIO – first approved in China, 25 February 2021
Vaccines_
- BioNTech-Pfizer
- Moderna
- AstraZeneca
- Johnson & Johnson
- Sputnik
Vaccines_Efficacy
Correlates of protection
Duration of immune response
Breakthrough infections and Transmissibility
Booster Dose
Two shots, two vaccines
One vaccine dose after previous SARS-CoV-2 infection
Vaccines_Adverse Events
VITT
Myocarditis
Anaphylaxis
Facial paralysis
Vaccines_Special populations
Older people
Pregnant women
Children
Co-morbidities
Cancer
Chronic lymphocytic leukemia (CLL)
Multiple myeloma
Solid Organ Transplant
IBD
Dialysis
Vaccines_Special topics
Post-exposure SARS-CoV-2 vaccination
Delayed booster injection
Protection of the non-vaccinated